The APHON Pediatric Chemotherapy-Biotherapy Provider Renewal Program provides ongoing education for current APHON Chemotherapy and Biotherapy Providers as they gain specific knowledge, according to national standards, that is needed to safely and consistently administer chemotherapy and biotherapy to children and adolescents.

To ensure that Pediatric Chemotherapy/Biotherapy Providers stay current in their knowledge of safe chemotherapy and biotherapy administration, APHON requires active Providers to renew their status every (2) two years after the completion and passing of their initial provider exam. 

The 2026 Provider Renewal Exam opens October 1, 2026. The last day to complete the renewal exam is December 15, 2026.

Why does my exam need to be completed by December 15?  Completion by this date ensures that all providers are successfully renewed and have certificates issued prior to the year end and holiday season which ensures no gap in your status.  

The Renewal Exam is a 90-minute, open-note, online assessment comprising 25 questions in both English and Spanish, and it is accessible at any point during the open renewal season (October 1, 2026 through December 15, 2026). Participants are granted (2) two attempts to successfully pass the exam, thereby renewing their status for another (2) two-year duration. In the event that a participant is unable to pass the exam during the open renewal season, it will be necessary for them to retake the initial Provider Course to reinstate their status. 

To view the current available public Provider Courses, please visit our Upcoming Provider Courses

Nurses who expect to be on FLMA or military deployment during their renewal season may request an exam extension before January 15, 2027. After this date, you will be required to retake the initial Provider Course.

If you are unsure about the expiration date of your provider status, the APHON Education Team encourages you to log into your Provider associated account and review your Provider Card where your expiration is listed.

  • Infusion Reactions  
  • Blinatumomab
  • We Are Nurses: A Research Review

Provider Renewal Guidelines